Bioventus Inc. (NASDAQ:BVS) Receives $14.00 Consensus Target Price from Analysts

Shares of Bioventus Inc. (NASDAQ:BVS) have received a consensus recommendation of “Buy” from the five analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $14.00.

Several research firms recently weighed in on BVS. Craig Hallum upped their price target on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 6th. CJS Securities began coverage on Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price target on the stock. Barrington Research reissued an “outperform” rating and set a $14.00 price target on shares of Bioventus in a research report on Friday, May 22nd. Finally, Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th.

Insiders Place Their Bets

In related news, Director Michelle Mcmurry-Heath sold 12,000 shares of the company’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the transaction, the director directly owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its stake in Bioventus by 17,156.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after purchasing an additional 5,490 shares in the last quarter. Covestor Ltd grew its stake in Bioventus by 28.0% in the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock valued at $67,000 after purchasing an additional 2,176 shares in the last quarter. SG Americas Securities LLC purchased a new position in Bioventus in the fourth quarter valued at about $80,000. Diversified Trust Co purchased a new position in Bioventus in the first quarter valued at about $100,000. Finally, Prelude Capital Management LLC purchased a new position in Bioventus in the third quarter valued at about $74,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Stock Down 6.8%

Shares of Bioventus stock opened at $7.93 on Tuesday. The stock’s fifty day moving average is $9.65 and its 200-day moving average is $8.54. The firm has a market capitalization of $662.47 million, a PE ratio of 19.34, a price-to-earnings-growth ratio of 1.10 and a beta of 0.67. The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08. Bioventus has a 12-month low of $5.81 and a 12-month high of $11.25.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.06. The firm had revenue of $132.09 million for the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities analysts anticipate that Bioventus will post 0.77 earnings per share for the current year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.